Due to popular demand, Life Sciences Pennsylvania will again host the Making the Most of Your Membership roundtable discussion.

This interactive seminar is designed for Life Sciences Pennsylvania members who are looking for ways to build and improve their life sciences network. The discussion will be led by longtime member Charlie Huntington (Senior Vice President-Investment Officer, Huntington Kraus Financial Group) ). Charlie will discuss their experiences and strategies related to growing a productive network and client base within the life sciences.

Topics to be covered include:

• How can I position my company as a valuable resource within the life science community?
• The life sciences are a unique industry; what do I need to know, and how do I learn it?
• What specific techniques will help me make the most of my Life Sciences Pennsylvania membership?

Agenda
8:00 AM – 8:20 AM: Coffee & Networking
8:20 AM – 9:30 AM: Presentation & Roundtable Discussion

Discussion led by:
Charlie Huntington, Senior Vice President-Investment Officer, Huntington Kraus Financial Group

*This event is for Life Sciences Pennsylvania members only. There is no cost to attend, however space is limited. Early registration is encouraged.

Hear from leading life sciences industry CEO’s about growth within their companies and the changing landscape of life sciences across Pennsylvania. Attendees can enjoy the benefit of a Q+A interactive panel, breakfast, and networking with industry leaders.

Agenda

7:30 a.m. – 8:15 a.m.     Registration & Networking

8:15 a.m. – 9:30 a.m.     Panel Discussion

Panelists:

Sue Dillon, President & CEO, Aro Biotherapeutics Company
Bethany Edwards, Co-founder and CEO, LIA Diagnostics
Gerri Henwood, President & CEO, Recro Pharma, Inc.

*This event is reserved for Life Sciences PA Core Members. This invitation is for those who serve in the capacity of Chief Executive Officer, Chief Science Officer, Chief Medical Officer, VP of Research & Development, and Head of Clinical Operations. If you are unsure of your eligibility, please contact Patrick Hayakawa, Director of Member Relations, phayakawa@lifesciencespa.org

**There is no registration fee. The cost for this event is fully underwritten by our generous sponsors.

About Bruce Levine, Ph.D.:

Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,200 patients in clinical trials since 1996. T lymphocytes from HIV+ subjects have been rendered resistant to HIV infection and reinfused. T lymphocytes from cancer patients have been redirected with chimeric antigen receptors (CAR’s) to hunt and destroy their malignancies. This therapy, developed by the CVPF and licensed by Novartis, recently became the first FDA approved gene therapy (Kymriah). Dr. Levine is co-inventor on 23 issued US patents and co-author of 140 publications with a Google Scholar citation h-index of 71. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. He has been interviewed by the NY Times, Wall Street Journal, Time Magazine, National Geographic, Forbes, BBC, and other international media outlets.